Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

(2013) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology

(2012) Claudia A. Dumitru et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Antigen-Specific CD4+ T Cells Regulate Function of Myeloid-Derived Suppressor Cells in Cancer via Retrograde MHC Class II Signaling

(2012) S. Nagaraj et al.   CANCER RESEARCH

Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma

(2012) A. Gros et al.   CLINICAL CANCER RESEARCH

Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-α or TLR-9 Agonist and GM-CSF With Peptide Vaccination

(2012) Ahmad A. Tarhini et al.   JOURNAL OF IMMUNOTHERAPY

Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cellsin vitroin a TLR4-independent manner

(2012) Tillmann Michels et al.   Journal of Immunotoxicology

Biomarkers on melanoma patient T Cells associated with ipilimumab treatment

(2012) Wenshi Wang et al.   Journal of Translational Medicine

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases

(2011) Jianda Yuan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

(2011) Paola Filipazzi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

(2011) Rachel F. Gabitass et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Targeting myeloid regulatory cells in cancer by chemotherapeutic agents

(2011) Hiam Naiditch et al.   IMMUNOLOGIC RESEARCH

Myeloid derived suppressor cells in human diseases

(2011) Tim F. Greten et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients

(2011) Lukas Baitsch et al.   JOURNAL OF CLINICAL INVESTIGATION

T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma

(2011) Michele Del Vecchio et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

(2011) Jeffrey S. Weber et al.   JOURNAL OF IMMUNOTHERAPY

Ipilimumab

(2011) Vernon K. Sondak et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

(2011) C. Garbe et al.   ONCOLOGIST

Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab

(2011) J. Yuan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Myeloid-Derived Suppressor Cells in Human Cancer

(2010) Srinivas Nagaraj et al.   CANCER JOURNAL

Immature Immunosuppressive CD14+HLA-DR−/low Cells in Melanoma Patients Are Stat3hi and Overexpress CD80, CD83, and DC-Sign

(2010) Isabel Poschke et al.   CANCER RESEARCH

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

The growing diversity and spectrum of action of myeloid-derived suppressor cells

(2010) Alberto Mantovani   EUROPEAN JOURNAL OF IMMUNOLOGY

Treating Cancer by Targeting the Immune System

(2010) Patrick Hwu   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma

(2010) Begoña Comin-Anduix et al.   PLoS One

Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance

(2010) V. A. Pedicord et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Adoptive cell therapy for the treatment of patients with metastatic melanoma

(2009) Steven A Rosenberg et al.   CURRENT OPINION IN IMMUNOLOGY

IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients

(2009) Susanna Mandruzzato et al.   JOURNAL OF IMMUNOLOGY

Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer

(2009) S. Ostrand-Rosenberg et al.   JOURNAL OF IMMUNOLOGY

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Sunitinib-Induced Myeloid Lineage Redistribution in Renal Cell Cancer Patients: CD1c+ Dendritic Cell Frequency Predicts Progression-Free Survival

(2008) H. van Cruijsen et al.   CLINICAL CANCER RESEARCH

Reversal of Myeloid Cell-Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma

(2008) S. Kusmartsev et al.   CLINICAL CANCER RESEARCH

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA